CARE reaffirms A+ rating to IOL Chemicals and Pharmaceuticals
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
elanese now offers Zytel Resin, Hytrel TPC, Crastin PBT and Micromax Electronic Inks and Paste following its 2022 acquisition of the majority of the Mobility & Materials (M&M) business from DuPont
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
The company has reported total income of Rs. 815.11 crores during the period ended March 31, 2023
These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
Subscribe To Our Newsletter & Stay Updated